Defunct Company
Total Trials
35
As Lead Sponsor
29
As Collaborator
6
Total Enrollment
3,165
NCT00003763
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
Phase: N/A
Role: Lead Sponsor
Start: Dec 8, 1997
Completion: May 3, 2000
NCT01689636
Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients
Phase: Phase 1
Start: Aug 31, 2000
Completion: Jul 31, 2002
NCT01686256
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
Start: Aug 31, 2001
Completion: Not specified
NCT01689662
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
Phase: Phase 2
Start: Aug 31, 2002
Completion: Jul 31, 2003
NCT01689727
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Start: Sep 30, 2002
NCT01684098
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Start: Aug 31, 2003
Completion: Aug 31, 2005
NCT01689714
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
NCT01689766
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Start: Nov 30, 2003
NCT00329368
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
Start: Sep 30, 2005
Completion: Jun 30, 2008
NCT00308269
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
Start: Mar 31, 2006
Completion: Jul 31, 2008
NCT00588393
FolateScan in Autoimmune Disease
Role: Collaborator
Start: Sep 30, 2006
Completion: Dec 31, 2007
NCT00441870
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
Start: Feb 28, 2007
Completion: Nov 30, 2010
NCT00485563
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Start: Jun 30, 2007
Completion: Mar 31, 2009
NCT00507741
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
Start: Aug 31, 2007
Completion: Apr 30, 2009
NCT00511485
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Completion: Nov 30, 2009
NCT00722592
Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)
Start: Sep 30, 2008
Completion: Dec 31, 2012
NCT00852189
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
Start: Apr 30, 2009
Completion: Apr 30, 2012
NCT01002924
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Start: Dec 31, 2009
Completion: Dec 11, 2013
NCT01237405
A Study of FolateScan in Patients With Knee Osteoarthritis
Start: Oct 31, 2010
Completion: Oct 31, 2012
NCT01577654
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Start: Mar 31, 2011
Completion: Aug 31, 2015
NCT01170650
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Phase: Phase 3
Start: Apr 22, 2011
Completion: Sep 8, 2015
NCT01688791
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Start: Dec 31, 2012
Completion: Sep 30, 2014
NCT01748864
Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers
Start: Apr 30, 2013
Completion: Oct 31, 2013
NCT01999738
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Start: Oct 31, 2013
Completion: Apr 26, 2018
NCT02049281
A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Start: Feb 28, 2014
Completion: May 31, 2014
NCT01953536
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Start: Apr 30, 2014
Completion: Nov 30, 2016
NCT02202447
Phase 1 of EC1169 In Patients With Recurrent MCRPC
Start: May 31, 2014
Completion: Nov 29, 2018
NCT03011320
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
Start: Jan 24, 2017
Completion: Aug 28, 2018
NCT03042312
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
Start: Jul 12, 2017
Completion: Jan 15, 2020
NCT03392428
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
Start: Jan 29, 2018
Completion: Dec 31, 2021
NCT03511664
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Start: May 29, 2018
Completion: Dec 14, 2023
NCT03494114
Imaging Activated Macrophages in the Lungs
Start: Nov 29, 2018
Completion: Jan 13, 2021
NCT04430192
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Phase: Phase 1/2
Start: Aug 6, 2020
Completion: Aug 30, 2025
NCT04419402
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
Start: Aug 17, 2020
Completion: Jan 1, 2025
NCT04597411
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Start: Apr 1, 2021
Completion: Jan 1, 2027